Figure 3 | Scientific Reports

Figure 3

From: Novel VEGFR2 inhibitors with thiazoloquinoxaline scaffold targeting hepatocellular carcinoma with lower cardiotoxic impact

Figure 3

Effect of daily treatment (3 days) of sorafenib or compound 4d [50 mg/ kg, p.o] on heart creatine kinase activity (CK, ng/mg) in 8 Gy irradiated mice. All values are plotted as mean ± S.E. * represented significance from Normal at P ≤ 0.05, # represented significance from IRR at P ≤ 0.05, s represented significance from IRR + sorafenib at P ≤ 0.05.

Back to article page